Abiopharma

🔍 Klamkin Jonathan (Executive)

Company: Aeluma, Inc. (ALMU)

Report Date: 2025-12-19

Detailed Transactions and Holdings:

• Sold 350,000 shares of Common Stock (Direct)
  Date: 2025-12-19 | Code: G | equity_swap_involved: 0 | shares_owned_after: 1,129,398.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 350,000 shares of Common Stock (Direct)
  Date: 2025-12-19 | Code: G | equity_swap_involved: 0 | shares_owned_after: 350,000.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,126,995 shares of Common Stock (Direct)
  Date: 2025-12-29 | Code: G | equity_swap_involved: 0 | shares_owned_after: 2,403.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 1,126,995 shares of Common Stock (Direct)
  Date: 2025-12-29 | Code: G | equity_swap_involved: 0 | shares_owned_after: 1,476,995.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 50,000 shares of Common Stock (Direct)
  Date: 2026-03-04 | Code: G | equity_swap_involved: 0 | shares_owned_after: 1,426,995.00 | transaction_form_type: 4
• Acquired 50,000 shares of Common Stock (Direct)
  Date: 2026-03-04 | Code: G | equity_swap_involved: 0 | shares_owned_after: 52,403.00 | transaction_form_type: 4
• Sold 20,000 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: G | equity_swap_involved: 0 | shares_owned_after: 1,406,995.00 | transaction_form_type: 4
• Acquired 20,000 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: G | equity_swap_involved: 0 | shares_owned_after: 22,403.00 | transaction_form_type: 4
• Sold 20,000 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: G | equity_swap_involved: 0 | shares_owned_after: 1,386,995.00 | transaction_form_type: 4
• Acquired 20,000 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: G | equity_swap_involved: 0 | shares_owned_after: 22,403.00 | transaction_form_type: 4
• Sold 4,300 shares of Common Stock at $24.1992 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 18,103.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 15,024 shares of Common Stock at $25.1487 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 3,079.00 | transaction_form_type: 4 | Footnotes: F2, F4
• Sold 676 shares of Common Stock at $25.7125 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,403.00 | transaction_form_type: 4 | Footnotes: F2, F5, F6

Footnotes:

• F1: In December 2025, the reporting person transferred 1,476,995 shares to a family trust for estate planning purposes. The reporting person and his spouse are the sole trustees.
• F2: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2025.
• F3: Reflects the weighted average price of 4,300 shares of common stock of Aeluma, Inc. sold by the reporting person in multiple transactions on May 1, 2026 with sale prices ranging from $23.62 to $24.61 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
• F4: Reflects the weighted average price of 15,024 shares of common stock of Aeluma, Inc. sold by the reporting person in multiple transactions on May 1, 2026 with sale prices ranging from $24.62 to $25.61 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
• F5: Reflects the weighted average price of 676 shares of common stock of Aeluma, Inc. sold by the reporting person in multiple transactions on May 1, 2026 with sale prices ranging from $25.62 to $26.02 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
• F6: Due to interim sales transactions previously reported on March 6, 2026 and April 3, 2026, amounts of securities beneficially owned following reported transactions may not foot.